Friday 4 February 2011
| 09:30–10:00 | Registration, refreshments and expenses |
| 10:00–10:05 | Welcome and UKCAB updates |
| 10:05–10.30 | Pre-Meeting for Gilead |
| 10:30–11:30 | iPrEX Trial design; statistical aspect of the results relating to the adherence data – Dr Colette Smith |
| 11:30–11:40 | Break |
| 11:40–12:40 | Science behind PrEP/Pharmacology Training; complexity of how drugs are absorbed and measured in different body compartments, and particularly for PrEP – Dr Steve Taylor, Heart of England NHS Trust, Birmingham |
| 12:40–14:00 | Lunch |
| 14:00–15:30 | Company meeting: Gilead |
| 15.30–15.35 | Break |
| 15:35–16:00 | UKCAB AOB |
| 16.00 | Close |
What happens to drugs in the body? (Fact sheet on pharmacokinetics)
http://i-base.info/ttfa/learning-resources/what-happens-when-you-take-a-drug
About iPrEX
http://www.globaliprex.com/Study.html
Treatment as prevention:
http://www.avert.org/hiv-treatment-as-prevention.htm
Many HIV Positive Women on Antiretroviral Therapy Have Detectable Virus in Genital Tract
http://www.hivandhepatitis.com/recent/2010/1210_2010_b.html
Studies Look at Antiretroviral Drug Levels in Genital Fluids, Prospects for Use in Microbicides
http://www.hivandhepatitis.com/2010_conference/croi/docs/0330_2010_a.html
AVAC’s resource page on PrEP, which will direct your attention to all sorts of reports and comment on the iPrEx trial and its implicaitons:
http://www.avac.org/ht/d/sp/i/3619/pid/3619
EATG’s report on an AVAC/EATG/NAM/EUROPRISE community advocates’ meeting in Brussels last September where the implications of PrEP were gone into in some detail
http://www.eatg.org/eatg/content/download/18873/146225/file/Meeting%20PrEP%20ECAB%20Final.pdf
Presentations from EATG meeting
Aidsmap’s original news reports on iPrEx are at
http://www.aidsmap.com/Anti-HIV-drugs-prevent-HIV-infection-trial-shows-if-you-take-them/page/1553857/
and
http://www.aidsmap.com/page/1555342/
Useful articles on the problem of measuring and supporting adherence in prevention trials
http://aidsmap.com/news/Adherence-to-ARV-prevention-methods-is-challenging-partly-because-they-don-t-treat-illness/page/1438915/
and
http://aidsmap.com/Microbicides-2008-Will-adherence-issues-affect-all-the-first-generation-trials/page/1429752/ (from a few years ago, but still relevant).
Presentations from this meeting
iPrEX Trial Design; statistical aspect of the results relating to the adherence data [PDF, 120Kb]
- Dr Colette Smith, Royal Free Hospital
Genital Tract ART Implications for transmission 2010 [PowerPoint presentation, 6MB]
- Dr Steve Taylor, Heart of England NHS Trust